Kantonsspital St.Gallen
login

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Hermann Reichegger, Wolfram Jochum, Diana Förbs, Claudia Hader & Martin Früh

abstract

BACKGROUND
Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

CASE REPORT
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.

CONCLUSION
These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.
   
citation Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.
   
type journal paper/review (English)
date of publishing 15-06-2016
journal title Oncol Res Treat (39/7-8)
ISSN electronic 2296-5262
pages 461-3
PubMed 27486808
DOI 10.1159/000446759